USANA Health Sciences, Inc. announced its preliminary financial results for the second quarter of 2022, including net sales of $265 million, down from $337 million during the same quarter last year. Earnings per share expectations were also down at $1.05, compared to $1.87 during the second quarter of 2022.
“Our sales performance during the second quarter was below expectations, as COVID-related lockdowns, restrictions, and other disruptions continued in mainland China and other markets,” said Kevin Guest, USANA Chief Executive Officer and Chairman of the Board. “These challenges were particularly disruptive to the regional sales program we offered in several key markets during the quarter, and ultimately caused participation in the program, sales results and active customer counts to come in lower than anticipated. Importantly, this program was designed to be a catalyst for sales and customer growth not only during the quarter, but also in the second half of the year. As a result of this and the continued uncertainty surrounding the operating environment going forward, we anticipate softer sales and customer counts in the second half of the year.”
The company plans to release its official financial report later this month.
